Drugs / Lactobacillus GG
Lactobacillus GG
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01545349 | Feb 2012 → May 2013 | influenza | Patricia L. Hibberd | Completed | No outcome recorded |
| Phase 1 | NCT01368029 | Sep 2011 → May 2012 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01274598 | Dec 2010 → Aug 2011 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00934453 | Dec 2009 → May 2012 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00992290 | Oct 2009 → Dec 2012 | hepatic encephalopathy | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04373512 | May 2020 → Feb 2025 | spinal cord injury | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00895336 | Mar 2011 → Mar 2012 | ulcerative colitis | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06636669 | Aug 2025 → Jun 2027 expected | immune dysregulation, neurodevelopmental defects, and colitis, periprosthetic joint infection | Boston Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT00304863 | Aug 2008 → Jul 2010 | Clostridium difficile colitis, enterocolitis | Michael E. DeBakey VA Medical Center | Withdrawn | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00220519 | Oct 2004 → May 2005 | — | Shriners Hospitals for Children | Terminated | No outcome recorded |
| — | NCT00224432 | Mar 2001 → Sep 2002 | atopic eczema | Groningen Research Institute for Asthma and COPD | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01782755 Comparator | Oct 2013 → Aug 2014 | Clostridium difficile colitis, diarrheal disease | McMaster University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02462590 Comparator | Jun 2015 → Mar 2019 | Clostridium difficile colitis, diarrheal disease | McMaster University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04898686 Comparator | Aug 2020 → Aug 2021 | allergic disease | University Hospital, Antwerp | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus GG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00992290 ↗ |
| Known as | Culturelle | “Patients receive 1 × 1010 colony forming units of L. rhamnosus GG (Culturelle, Locin Industries Ltd) or an identical placebo suspended in tap water administered twice daily via...” NCT01782755 ↗3“Culturelle probiotic, one capsule daily to start following SOC surgical treatment for PJI during the initial 6 weeks of SOC antibiotic treatment.” NCT06636669 ↗ “L. rhamnosus GG (Culturelle, Locin Industries Ltd)” NCT02462590 ↗ |
| Known as | L. rhamnosus GG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01782755 ↗ |
| Known as | Lacticaseibacillus rhamnosus GG | “chewables containing Lacticaseibacillus rhamnosus GG” NCT04898686 ↗ |
| Known as | Lactobacillus rhamnosus GG | “The aim of the PROSPECT Pilot Trial is to determine the feasibility of performing a larger trial in mechanically ventilated critically ill patients investigating Lactobacillus...” NCT01782755 ↗ |
| Known as | Lactobacillus rhamnosus GG ATCC 53103 | “Lactobacillus rhamnosus GG ATCC 53103 (LGG) has been consumed by 2 to 5 million people daily since the mid 1990s, there are few clinical trials describing potential harms of...” PMID 25438151 ↗ Dec 2014 |
| Known as | Lactobacillus rhamnosus GG ATCC 53103 (LGG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01545349 ↗ |
| Known as | LGG | “This proposal intends to define Lactobacillus GG (LGG) as a biologically-based alternative therapy for MHE with special focus on metabolic and stool bacteriologic changes.” NCT00992290 ↗ |
| Modality | Other / unclassified | “Lactobacillus GG, a probiotic, replenishes the healthy flora of the intestinal tract and may decrease the risk of diarrhea and infection during critical illness.” NCT00220519 ↗ |
| Route | Oral | “All supplements will be administered orally or via feeding tube.” NCT00220519 ↗ |